We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.
As some are now calling it, the greater Philadelphia region, or ‘Cellecon Valley, is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US.
Philadelphia-based CARISMA Therapeutics Inc. secured $47 million in a Series B financing round that will be used to advance the development of the company’s novel chimeric antigen receptor macrophages (CAR-M) immunotherapies.
